Is imatinib mesylate a promising drug in systemic sclerosis?

Arthritis and Rheumatism

Volumn 58, Issue 8, 2008, Pages 2549-2552

  Van Daele, P L A ^a   Dik, W A ^a   Thio, H B ^a   Van Hal, P Th W ^a   Van Laar, J A M ^a   Hooijkaas, H ^a   Van Hagen, P M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMATINIB; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BRONCHUS BIOPSY; CASE REPORT; CELL PROLIFERATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FIBROBLAST CULTURE; GENERAL CONDITION DETERIORATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPONATREMIA; IN VITRO STUDY; INCUBATION TIME; LOW DRUG DOSE; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG LAVAGE; PRIORITY JOURNAL; SKIN TIGHTNESS; SYSTEMIC SCLEROSIS;

AGED; COLLAGEN; DISEASE PROGRESSION; FEMALE; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 49449114399     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23648     Document Type: Article

References (11)

1. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367:1683-91.
2. Sakkas LI, Platsoucas CD. Is systemic sclerosis an antigen-driven T cell disease? [review]. Arthritis Rheum 2004;50:1721-33.
3. Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, et al. Elevated levels of platelet derived growth factor and transforming growth factor-β1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995;22:1876-83.
4. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76.
5. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-16.
6. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. Nat Med 1996;2:561-6.
7. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
8. Dik WA, Versnel MA, Naber BA, Janssen DJ, van Kaam AH, Zimmermann LJ. Dexamethasone treatment does not inhibit fibroproliferation in chronic lung disease of prematurity. Eur Respir J 2003;21:842-7.
9. Dik WA, Pike-Overzet K, Weerkamp F, de Ridder D, de Haas EF, van der Spek P, et al. New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling. J Exp Med 2005;201:1715-23.
10. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
11. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16.